We continue to investigate the use of our proprietary extended-release drug delivery technology platform to meet various unmet medical needs. Our FDA approved products and future product candidates include the following attributes and administration features:
- An extended-release profile, providing the convenience of once-daily dosing
- Designed with patients in mind
- ODT that disintegrates in the mouth without water
- Liquid suspension
- Taste-masking of bitter medications, with flavoring options
- Convenient single-unit blister packaging, which is portable and discreet
Our Proprietary Technology Platform
We are able to apply the XR-ODT and XR oral suspension technologies to other active pharmaceutical ingredients, or APIs. We have the ability to produce drug-loaded micro-particles with complex release profiles, which allows us to develop ODT or oral suspension formulations that can mimic various release profiles not otherwise available in XR-ODT or XR oral suspension form.
Rapidly Disintegrating Ionic Masking – XR ODT
Our Rapidly Disintegrating Ionic Masking, or RDIM, technology utilizes an orally disintegrating, extended-release, taste-masked pharmaceutical composition that can withstand compression forces associated with standard tableting technology, allowing for a drug to be incorporated into the ODT dosage form using ion resin technology. This technology not only provides extended-release and controlled-release properties, it is designed to mask the taste of the active drug.
Dynamic Time Release Suspension® – XR Oral Suspension
Our Dynamic Time Release Suspension®, or DTRS®, technology encompasses a set of process technologies and know-how to manufacture and test extended-release oral suspension products that are shelf-stable. Our DTRS® technology not only provides for an extended-release, ready-to-use oral suspension but may offer taste-masking of the active pharmaceutical ingredient.
Kinetically Controlled Tamper Protection – XR ODT and XR Oral Suspension
Our Kinetically Controlled Tamper Protection™, or KCTP™, technology is designed to prevent abuse by altering the kinetics of the drug product and can be used in conjunction with both our XR-ODT and XR oral suspension dosage forms. We believe that our KCTP™ technology can be applied to opioid-based pain products or other DEA scheduled drug products for which abuse and dose dumping are known problems.